Angitia Biopharmaceuticals Doses First Patient in Phase 2 Trial of AGA2118 for Osteoporosis
核心洞察
Angitia Biopharmaceuticals has initiated a Phase 2 clinical trial (ARTEMIS) of AGA2118 for treating postmenopausal osteoporosis (搜索).
The ARTEMIS trial is a randomized, double-blind, placebo-controlled study involving approximately 350 postmenopausal women.
AGA2118, a bispecific antibody, targets sclerostin (搜索) and DKK1 (搜索) to enhance bone mineral density (BMD) in osteoporosis (搜索) patients.
Angitia Biopharmaceuticals has announced the dosing of the first patient in its Phase 2 ARTEMIS trial, evaluating AGA2118 for the treatment of osteoporosis (搜索). This randomized, double-blind, placebo-controlled study, conducted across the US and EU, aims to assess the efficacy of AGA2118 in increasing bone mineral density (BMD) in postmenopausal women. The trial plans to enroll approximately 350 participants.
AGA2118: A Novel Bispecific Antibody
AGA2118 is a bispecific antibody targeting sclerostin (搜索) and DKK1 (搜索), two key negative regulators of the WNT signaling pathway involved in bone metabolism. By inhibiting both proteins, AGA2118 aims to prevent compensatory increases of either agent, potentially leading to improved BMD gains in osteoporotic patients. Angitia Biopharmaceuticals wholly owns the rights to this antibody.
Trial Design and Endpoints
The ARTEMIS trial's primary endpoint is the percent change from baseline in BMD at the lumbar spine at 12 months. Secondary endpoints include percent changes in BMD at other anatomical locations and time points, as well as changes in biochemical markers of bone turnover. The study also includes an open-label extension through Month 24.
Osteoporosis: An Unmet Medical Need
Osteoporosis (搜索) is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to increased bone fragility and fracture risk. It is a global epidemic, affecting more than 200 million people worldwide, particularly older women. While several approved therapies exist, limitations in efficacy and safety persist, leaving a significant unmet medical need for new osteoporosis treatments.
Prior Clinical Data
First-in-human data on AGA2118, presented at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting, demonstrated rapid and robust gains in bone mineral density, according to Dr. Willard H. Dere, M.D., Chief Medical Officer of Angitia. The Phase 2 study is expected to build on these findings, further evaluating the potential of AGA2118 as a differentiated therapy for osteoporosis (搜索).
Angitia's Broader Pipeline
In addition to AGA2118, Angitia Biopharmaceuticals is studying three other biologic product candidates in clinical trials for the treatment of osteogenesis imperfecta (搜索) (OI) and spinal fusion.